Loading clinical trials...

COMPLETEDNA

Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders

NCT05211063•University of Alicante

Summary

Previous research has shown the efficacy of CROCUVIS+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. The main objective of this study is to evaluate the efficacy of CROCUVIS® in computer vision syndrome, sleep and mood disorders in a sample of university students who use digital devices.

Eligibility

Age

18 - 40 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•CVS-Q© score ≥6.
•Age between 18 and 40 years (both inclusive).
•Exposure to digital devices 4 hours a day, at least five days a week or more and maintain the same level of exposure throughout the study period.

Exclusion Criteria

•Monocular corrected distance visual acuity \>0.0 LogMAR.
•Ocular pathology under treatment at the time of the study.
•Previous ocular surgery that could affect the tear film or the ocular surface.
•Ocular Surface Disease Index (OSDI) questionnaire score ≥13.
•Previous diagnosis or history of dry eye syndrome and/or blepharitis.
•Regular (daily) use of rigid or soft contact lenses ≥3 days a week.
•Regular use of any ocular lubricant.
•History of oral intake of dietary supplements, with or without herbal ingredients, intended to contribute, maintain or reduce the risk of suffering diseases related to visual function, mood or sleep within the four weeks before the study enrollment.
•Systemic disease:
•1. Uncontrolled hypertension (systolic/diastolic blood pressure \>140/90 mmHg).
+20 more criteria

Locations (1)

University of Alicante

San Vicent del Raspeig, Alicante, Spain

Key Dates

Start Date

October 21, 2022

Primary Completion Date

December 27, 2022

Completion Date

May 5, 2023

Last Updated

May 11, 2023

Enrollment

100

ACTUAL participants

Conditions

Computer Vision SyndromeSleep DisorderMood Disorders

Interventions

Saffron extract (Crocus sativus)

DIETARY_SUPPLEMENT

Placebo

DIETARY_SUPPLEMENT

Behavioral Treatment for Nightmares in REM Sleep Behavior Disorder

NCT06441864

NightmareNightmare Disorder With Associated Other Sleep Disorder+1 more

View study

RECRUITING

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

NCT07426991

Multiple SclerosisRemitting-Relapsing Multiple Sclerosis+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 11, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders

Inclusion Criteria

Exclusion Criteria

Behavioral Treatment for Nightmares in REM Sleep Behavior Disorder

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Assessment of the Association Between Sleep Disorders Detected by a Simplified Questionnaire and Cardiovascular Diseases

Sleep Quality and Caregiver Burden in Children With Cerebral Palsy

Epidemiology of Sleep Disordered Breathing in Children and Young People With Cerebral Palsy

Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers